Loading clinical trials...

COMPLETEDPHASE2/PHASE3

A Pilot Study of Oxaloacetate in Subjects With Treated PD

A Pilot Double-Blind, Parallel Group, Placebo Controlled Study of Oxaloacetate in Subjects With Treated Parkinson's Disease (PD)

NCT01741701•University of Kansas Medical Center

View on ClinicalTrials.gov

Summary

The purpose of this study is to determine if Oxaloacetate (OAA) is a safe and effective treatment for Parkinson's disease. Each subject will be asked to make 3 study visits and complete two safety follow-up phone calls over a 4 month period.

Eligibility

Age

30 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Able to give informed consent and follow instructions per the protocol
•Diagnosis of idiopathic PD within 7 years of diagnosis
•Taking stable doses of levodopa and would not predictably need adjustment in PD medications for 4 months
•Unified Parkinson's Disease Rating Scale (UPDRS) II + III at least 30 points at baseline

Exclusion Criteria

•Previously taken Oxaloacetate
•Participation in other drug studies or use of other investigational products within 30 days prior to baseline
•In the Investigator's opinion, any unstable or clinically significant condition that would impair the subjects' ability to comply with study follow-up
•Other known or suspected cause of parkinsonism

Locations (1)

University of Kansas Medical Center

Kansas City, Kansas, United States

Key Dates

Start Date

December 1, 2012

Primary Completion Date

October 1, 2014

Completion Date

October 1, 2014

Last Updated

March 17, 2016

Enrollment

ACTUAL participants

Conditions

Parkinson's Disease

Interventions

Oxaloacetate (OAA)

DRUG

Placebo

DRUG

Deep Brain Stimulation Therapy in Movement Disorders

NCT02119611

Parkinson's Disease

View study

RECRUITINGPHASE1

Research Into the Safety of a New Agent (VT-5006) in People With and Without Parkinson's Disease

NCT07310264

Healthy Volunteers (HV)Parkinson's Disease (PD)

View study

RECRUITINGNA

Adaptive DBS Algorithm for Personalized Therapy in Parkinson's Disease (ADAPT-PD) China Study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: March 17, 2016Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

A Pilot Study of Oxaloacetate in Subjects With Treated PD

Inclusion Criteria

Exclusion Criteria

Deep Brain Stimulation Therapy in Movement Disorders

Research Into the Safety of a New Agent (VT-5006) in People With and Without Parkinson's Disease

Adaptive DBS Algorithm for Personalized Therapy in Parkinson's Disease (ADAPT-PD) China Study

A Study to Evaluate the Efficacy and Safety of Intravenous (IV) Prasinezumab in Participants With Early-Stage Parkinson's Disease

Effect of Striatal Temporal Interference Stimulation on Language Processing in Neurodegenerative Diseases

SAD Study in Patients With Parkinson's Disease and Motor Fluctuations